Acute Myeloid Leukemia Whole Blood
Fresh whole blood from IRB-consented donors with confirmed acute myeloid leukemia, a myeloid neoplasm defined by blocked differentiation and circulating blasts. Useful for FLT3/NPM1/IDH1/IDH2 mutation assay development, measurable residual disease methodology, blast immunophenotyping and targeted therapy research.
Acute Myeloid Leukemia Whole Blood for Haematologic Oncology Research
Acute Myeloid Leukemia (AML) Whole Blood is collected from IRB-consented donors with a clinically confirmed AML diagnosis and shipped same day. AML is an aggressive myeloid neoplasm in which transformed haematopoietic progenitors lose the capacity to differentiate and accumulate as blasts in bone marrow and peripheral blood, displacing normal haematopoiesis. Classification and treatment are increasingly driven by recurrent genetic lesions, and these fresh samples support tumour genomics, minimal residual disease methodology and targeted therapy research.
Leukaemic Transformation, Molecular Drivers and Why Whole Blood
- AML is a clonal neoplasm of myeloid progenitors. Blocked differentiation and unchecked proliferation produce circulating blasts, which is what makes peripheral whole blood informative rather than only marrow.
- Recurrent driver lesions define prognostic groups and therapeutic options. FLT3 internal tandem duplications and tyrosine kinase domain mutations, NPM1 mutations, and IDH1/IDH2 mutations each have licensed or investigational targeted agents.
- Cytogenetic abnormalities, including core-binding factor rearrangements and complex karyotypes, remain central to risk stratification alongside molecular findings.
- Blast immunophenotype by multiparameter flow cytometry is used both diagnostically and to define the marker combinations used for measurable residual disease tracking — work that requires viable nucleated cells.
- Whole blood preserves leukaemic blasts, residual normal leukocytes and the plasma compartment together, allowing paired genomic, immunophenotypic and circulating-analyte analysis from one collection.
- Circulating tumour DNA and cell-free nucleic acid approaches to AML monitoring can be developed from the plasma fraction of the same donor sample.
Donor Stratification Available
- Molecular profile where documented: FLT3, NPM1, IDH1/IDH2, CEBPA, TP53
- Cytogenetic risk group where available
- Disease status: newly diagnosed, on treatment, in remission, or relapsed/refractory
- De novo versus secondary AML arising from a prior myeloid neoplasm
- Treatment history: intensive chemotherapy, hypomethylating agents, venetoclax-based regimens, targeted inhibitors, or prior transplant
- Matched healthy controls available
Product Features
- Fresh whole blood from clinically diagnosed AML donors
- Custom anticoagulants and collection tubes available
- Same-day collection and shipment
- Custom volumes available on request
- Research Use Only (RUO)
De-identified Donor Data
- Physician-confirmed AML diagnosis, including FLT3/NPM1/IDH1/IDH2 status where available
- Demographics: age, sex assigned at birth, ethnicity
- Relevant medical and treatment history
- Disease status at collection and blast percentage where documented
Applications
- FLT3, NPM1 and IDH1/IDH2 mutation detection assay development
- Measurable residual disease methodology development by flow cytometry and molecular methods
- Blast immunophenotyping and leukaemia-associated immunophenotype characterisation
- Targeted inhibitor sensitivity and resistance research in primary cells
- Bulk and single-cell transcriptomic profiling of leukaemic and residual normal populations
- Circulating tumour DNA and cell-free nucleic acid assay development
- Immuno-oncology target discovery, including AML surface antigen and CAR-T target validation
- Tumour immunology and T cell exhaustion profiling in the leukaemic setting
Other Acute Myeloid Leukemia Specimen Types
Looking for the lymphoblastic form? See our Acute Lymphoblastic Leukemia Whole Blood product, or our Myelodysplastic Syndrome Whole Blood for related myeloid neoplasms.
Compliance and Quality Assurance
- IRB-approved protocols and electronic informed consent
- HIPAA-compliant donor data handling
Ordering & Customization
AML whole blood is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, email learnmore@sanguinebio.com. To browse donor cohorts across our full inventory, visit our human whole blood page.
Whole Blood
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Whole Blood cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.